

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

PROFIT WARNING

This announcement is made by Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 (the “**Interim Period**”) and other information currently available to the Company, as compared to the corresponding period in 2021, the Company is expected to record a decrease in profit attributable to owners of the Company in a range of approximately HK\$2.3 million to HK\$3.8 million for the Interim Period as compared to the same period in 2021, representing an expected drop of approximately 21% to 34%. The adjusted net profit is expected to be decreased in a range of approximately HK\$10.4 million to HK\$11.9 million for the Interim Period as compared to the same period in 2021, representing an expected drop of approximately 54% to 62%.

The adjusted net profit represents profit attributable to owners of the Company for the periods excluding the effects of the expenses related to the listing of the Company’s shares on the Main Board of the Stock Exchange.

The expected decrease of adjusted net profit was primarily due to the expected decrease in revenue and increase in employee benefit expenses. Due to the economic downturn and increased competition from other industry players, the Group's revenue was affected during the Interim Period. In order to support the Group's business expansion and to maintain the Group's competitiveness, the Company is expected to record an increase in employee benefit expenses during the Interim Period.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 September 2022. The information contained in this announcement is only a preliminary assessment based on the unaudited consolidated management accounts of the Group and the information currently available for the time being, which have not been audited nor reviewed by the Company's auditors and have not been confirmed by the audit committee of the Company and is subject to adjustments. The financial results of the Group for the six months ended 30 September 2022 will be set out in the interim results announcement of the Company which is expected to be published by the end of November 2022.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 7 November 2022

As at the date of this announcement, the Board comprises Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. NG Roy and Ms. ZHAO Wei as non-executive Directors and Mr. LI Michael Hankin, Mr. MA Wai Hung Vincent and Professor LAU Wan Yee Joseph as independent non-executive Directors.